Navigation Links
Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
Date:11/9/2010

SAN DIEGO, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Citi 7th Annual US Small/Mid Cap Conference in Las Vegas, Nevada on Tuesday, November 16, 2010 at 12:25 p.m. ET / 9:25 a.m. PT. Alex Casdin, vice president, finance at Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
3. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
4. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
5. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
9. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... OXFORD, England , August 26, 2015 ... P2i Ltd against Europlasma NV relating to P2i ... parties have resolved their dispute in the United ... or liability on the part of either party. As a ... the Central District of California dismissed ...
(Date:8/26/2015)... , ... August 26, 2015 , ... The 2015 Epigenomics ... adult stem cell technology start-up company Asymmetrex to share the first report ... of a new biomarker for counting adult tissue stem cells. , With a name ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... EMERYVILLE, Calif., Feb. 14 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... annual Research & Development Day to be held on ... 8:00 to 9:30 a.m. at the Mandarin,Oriental Hotel, 80 ... The focus of the meeting will be Viprinex(TM) ...
... in experienced industry professionals to help grow U.S. ... ... /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s first commercially,available ... design teams to bolster growing demand in the,United States., Bill Graham ...
... Tenn., Feb. 14 Accelerated Community Oncology,Research ... of a Phase,2b clinical trial evaluating the ... the anticancer drug gemcitabine (Gemzar(R)) in patients,with ... during or after,treatment with bevacizumab (Avastin(R))., ...
Cached Biology Technology:Touch Bionics adds to sales, marketing, production and design teams 2Touch Bionics adds to sales, marketing, production and design teams 3Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 2Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 3
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... have an extraordinary ability to remember numerals that is ... the December 4th issue of Current Biology, a publication ... including many biologists, who believe that humans are superior ... of Kyoto University. No one can imagine that chimpanzeesyoung ...
... to date of 130 North American tree species concludes ... ranges northward by hundreds of kilometers and shrink the ... W. McKenney of the Canadian Forest Service and his ... , McKenneys study is based on an extensive data-gathering ...
... gene involved in the disease Lupus, which affects around 50,000 ... the study has called for more patients to volunteer DNA ... of the disease. Lupus or Systemic Lupus Erythematosus ... rash, joint pains and malaise, but can also lead to ...
Cached Biology News:Young chimps top adult humans in numerical memory 2Climate change predicted to drive trees northward 2Lupus gene finding prompts call for more DNA samples 2
... CC1041 is a recombinant 177 amino ... Gly265 of mature human MT1-MMP. Produced ... of MT1-MMP purified from E. coli periplasm. ... catalytic domain is = 140 mU/mg, where ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
QCPN...
Biology Products: